Logo
x

Search

Subscribe Now

ATTR Amyloidosis Programme

Novo Nordisk to Acquire Prothena's ATTR Amyloidosis Program for ~$1.2B

Novo Nordisk to Acquire Prothena's ATTR Amyloidosis Program for ~$1.2B

  • July 13, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.